Search

Mirati Therapeutics Inc

Nyitva

SzektorEgészségügy

0

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

Maximum

Ajánlások

By TipRanks

Ajánlások

Semleges

12 hónapos előrejelzés

-0.05% downside

Hangulat hírek alapján

By Acuity

28%

72%

65 / 340 Rangsor szerint Healthcare

Mirati Therapeutics Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. júl. 22. 23:56 UTC

Correlated Moves
News

American Water Works Company Inc. is trading lower in after-market hours amid geopolitical tensions and rising crude oil prices impacting market sentiment.

2026. júl. 22. 23:56 UTC

News

Wynn Resorts received approval to expand its Wynn Palace resort in Macau, including a new hotel and entertainment center. Shares showed little change in after-market trading.

2026. júl. 22. 23:51 UTC

News

Rollins Inc shares fell after second-quarter results missed expectations. Adjusted EPS was $0.32, below the consensus estimate of $0.34, amid slowing growth.

2026. júl. 22. 23:51 UTC

Social Media
News

CSX Corp reported second-quarter revenue of $3.94 billion and EPS of $0.54, exceeding expectations, leading to higher shares in after-market trading.

2026. júl. 22. 23:51 UTC

Social Media
News

Joby Aviation will release its Q2 2026 results on August 5, generating positive investor sentiment. Shares are trading higher in after-market hours.

2026. júl. 22. 23:51 UTC

Social Media
News

Southwest Airlines reported second-quarter earnings above estimates but missed on revenue, leading to shares trading lower in after-market hours.

2026. júl. 22. 23:51 UTC

News

Norfolk Southern Corp shares are trading lower in after-market hours following Union Pacific and Canadian National Railway's agreement that may impact its competitive position.

2026. júl. 22. 23:51 UTC

ETF Constituents
Social Media
News

Invesco QQQ Trust Series I is lower in after-market hours amid concerns over rising crude oil prices and geopolitical tensions affecting market sentiment.

2026. júl. 22. 23:51 UTC

Social Media
Correlated Moves
News

Amazon.com Inc is under Senate investigation for alleged Chinese influence on its marketplace, contributing to a decline in investor sentiment and stock price after hours.

2026. júl. 22. 23:51 UTC

ETF Constituents
News
Macro News

Vanguard Information Technology ETF is higher in after-market hours, driven by positive sentiment ahead of earnings from major tech firms and strong performances from key holdings.

2026. júl. 22. 23:46 UTC

News

EQT Corporation's stock rose after it raised full-year natural gas production guidance and secured long-term supply agreements, despite lower-than-expected earnings.

2026. júl. 22. 23:46 UTC

Social Media
News

Intel explores a partnership with SK Hynix for its Ohio facility. Shares are trading higher after securing Fortinet as its first external foundry customer.

2026. júl. 22. 23:46 UTC

Social Media
News

Crown Castle reported second-quarter adjusted FFO of $1.13, exceeding estimates. Shares are higher in after-market trading following the results and strategic business sale.

2026. júl. 22. 23:41 UTC

News

Goosehead Insurance shares rise in after-market hours following strong Q2 results, with revenue of $113.4 million and a leadership transition announcement.

2026. júl. 22. 23:41 UTC

News

Community Health Systems reported a significant decline in net income and lowered its full-year EPS guidance, leading shares to trade lower in after-market hours.

2026. júl. 22. 23:41 UTC

Social Media
News

Kinder Morgan's Q2 earnings of $0.37 per share exceeded estimates, driving shares higher in after-market trading. Revenue rose to $4.48 billion, surpassing expectations.

2026. júl. 22. 23:36 UTC

Social Media
Correlated Moves
News

Shutterstock shares are lower in after-market hours following the suspension of dividends and the resignation of Chief Accounting Officer Steven Ciardiello.

2026. júl. 22. 23:36 UTC

Correlated Moves
News

Microsoft shares are lower in after-market hours amid a securities class action lawsuit regarding its Copilot products and concerns over capital expenditures ahead of earnings.

2026. júl. 22. 23:36 UTC

Social Media
News

Rocket Lab shares are lower in after-market hours, reflecting broader sector trends. The company will release second-quarter 2026 results on August 10, 2026.

2026. júl. 22. 23:31 UTC

Social Media
News

Leslie's Inc shares declined in after-hours trading amid reports of a potential Chapter 11 bankruptcy, raising concerns about the company's financial stability.

2026. júl. 22. 23:26 UTC

News

Synopsys Inc will report third-quarter results on August 26, 2026, after market close. Shares are trading higher in after-market hours.

2026. júl. 22. 23:22 UTC

Social Media
News

Tesla Inc. shares declined in after-hours trading following a Q2 earnings miss, with adjusted EPS at $0.33 against expectations of $0.51.

2026. júl. 22. 23:22 UTC

Social Media
News

Medpace Holdings Inc. reported Q2 revenue of $707.3 million, exceeding expectations, and raised 2026 guidance, driving shares higher in after-market trading.

2026. júl. 22. 23:16 UTC

News

Hims & Hers Health shares declined to about $31.66 after mixed options sentiment, with calls outpacing puts amid lighter trading volume.

2026. júl. 22. 23:16 UTC

News

Interactive Brokers reported second-quarter net revenue growth of 28% to $1.90 billion, driven by a 67% increase in customer margin loans.

2026. júl. 22. 23:11 UTC

Social Media
News

Lockheed Martin announced a quarterly dividend of $3.45 per share, boosting investor sentiment. Shares are higher in after-market trading following the announcement.

2026. júl. 22. 23:06 UTC

News

Constellation Energy Corp shares are lower in after-market trading, influenced by geopolitical tensions and concerns over potential oil supply disruptions.

2026. júl. 22. 23:06 UTC

News

Dollar Tree shares are lower in after-market trading amid scrutiny over new price scanners and rising costs, prompting concerns about customer loyalty.

2026. júl. 22. 23:06 UTC

News

General Motors raised its 2026 profit outlook to $14 billion to $16 billion, boosting shares higher in after-market hours following strong EBIT performance.

2026. júl. 22. 23:02 UTC

Social Media
News

QuantumScape Corp's shares declined in after-market hours following a narrower loss and lowered capital expenditures guidance amid concerns over future cash flow.

Társak összehasonlítása

Árváltozás

Mirati Therapeutics Inc Előrejelzés

Célár

By TipRanks

-0.05% elmozdulás lefelé

12 hónapos előrejelzés

Átlag 58.67 USD  -0.05%

Magas 59 USD

Alacsony 58 USD

5 Wall Street elemző 12 hónapos célárain alapulva a(z)Mirati Therapeutics Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Semleges

5 ratings

0

Vétel

5

Tartás

0

Eladás

Hangulat

By Acuity

65 / 340 Rangsor szerint Egészségügy

Hangulat hírek alapján

Bullish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

EBITDA

Üzemi nyereség

$

Rólunk Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.
help-icon Live chat